Published in J Cardiovasc Med (Hagerstown) on December 01, 2016
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA (2007) 4.59
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med (2005) 4.27
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol (2007) 3.92
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med (2007) 2.95
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation (2010) 2.77
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J (2008) 2.71
Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail (2008) 2.69
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (2002) 2.47
Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA (2007) 2.43
Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med (2008) 2.42
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol (2006) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J (2004) 2.32
Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl (2007) 2.31
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J (2009) 2.28
Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA (2013) 2.17
Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol (2005) 2.16
Risk stratification after hospitalization for decompensated heart failure. J Card Fail (2004) 2.04
Testing bioequivalence for multiple formulations with power and sample size calculations. Pharm Stat (2012) 2.03
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail (2015) 2.03
A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J (2007) 2.01
National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transpl (2013) 2.00
O2, anybody? Eur J Anaesthesiol (2015) 1.99
Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation (2003) 1.99
Role of baseline echocardiography in the preoperative management of liver transplant candidates. Am J Cardiol (2012) 1.98
Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail (2008) 1.97
The role of the emergency department in acute heart failure clinical trials--enriching patient identification and enrollment. Am Heart J (2013) 1.95
A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry. J Hepatol (2011) 1.94
Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol (2011) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes (2011) 1.88
Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation (2010) 1.84
Associations between outpatient heart failure process-of-care measures and mortality. Circulation (2011) 1.77
Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol (2008) 1.75
Evidence-based use of levosimendan in different clinical settings. Eur Heart J (2006) 1.73
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. J Card Fail (2006) 1.72
Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation (2011) 1.71
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation (2011) 1.71
Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol (2006) 1.68
The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J (2011) 1.66
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol (2012) 1.64
Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol (2006) 1.64
The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther (2008) 1.63
Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail (2008) 1.63
Development and performance of a two-step desflurane-O(2)/N(2)O fresh gas flow sequence. J Clin Anesth (2008) 1.63
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
A propensity matched study of the association of education and outcomes in chronic heart failure. Int J Cardiol (2007) 1.62
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Lifetime risk and years lived free of total cardiovascular disease. JAMA (2012) 1.57
Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J (2012) 1.57
The Valsalva maneuver: a bedside "biomarker" for heart failure. Am J Med (2006) 1.57
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol (2003) 1.56
Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol (2012) 1.53
Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. Heart Rhythm (2009) 1.53
Thirty-day readmissions: the clock is ticking. JAMA (2013) 1.53
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol (2009) 1.50
Kidney transplant candidates' understanding of increased risk donor kidneys: a qualitative study. Clin Transplant (2011) 1.48
Early Postoperative Emergency Department Care of Abdominal Transplant Recipients. Transplantation (2015) 1.48
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J (2013) 1.47
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J (2009) 1.47
Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol (2012) 1.46
Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS (2016) 1.45
Day of admission and clinical outcomes for patients hospitalized for heart failure: findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Circ Heart Fail (2008) 1.44
A model for reactivation of CMV from latency. J Clin Virol (2002) 1.43
Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol (2010) 1.43
Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). Am J Cardiol (2010) 1.43
Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail (2005) 1.42
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol (2003) 1.41
National survey of adult transplant hepatologists on the pediatric-to-adult care transition after liver transplantation. Liver Transpl (2015) 1.41
Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart (2011) 1.41
Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA (2008) 1.40
The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery (2009) 1.39